JACOBIO Pharmaceuticals Group Co., Ltd. (stock code: 01167) disclosed a further share repurchase on 17 March 2026.

Key transaction details • Volume: 144,000 ordinary shares, acquired on the Hong Kong Stock Exchange. • Price range: HKD 6.92–7.02 per share; volume-weighted average price: HKD 6.98. • Cash outlay: HKD 1.00 million.

Capital structure impact • Issued shares (excluding treasury shares) fell by 0.018 % to 786.49 million. • Treasury stock rose to 5.27 million shares, while total issued shares remained unchanged at 791.76 million.

Repurchase mandate utilisation • Mandate approval date: 10 June 2025. • Authorised ceiling: 78.87 million shares. • Cumulative buybacks under the mandate: 2.25 million shares, equal to 0.28 % of the company’s issued shares on the mandate date.

Additional notes • All 144,000 repurchased shares are being held as treasury shares; none have been cancelled. • In accordance with HKEX rules, JACOBIO is restricted from issuing new shares or disposing of treasury shares until 16 April 2026.